Literature DB >> 20356316

Menopause Rating Scale as a screening tool in rural Turkey.

Selma Metintas1, Inci Arýkan, Cemalettin Kalyoncu, Sinan Ozalp.   

Abstract

INTRODUCTION: Women living in rural areas of Turkey experience difficulties in accessing healthcare services, and this is attributed to distance from urban healthcare centers, financial barriers and poverty, a low education level, and gender discrimination. The purpose of this study was to test the applicability of the menopause rating scale (MRS) as a screening tool by primary healthcare professionals for identifying women with severe menopausal symptoms. The objectives of the study were to test the validity and reliability of the MRS in rural areas of Turkey, to determine estimation values for referral to the secondary level of healthcare, and to assess the prevalence of severe menopausal symptoms among rural Turkish women.
METHODS: The sample size was 600 women. The Turkish version of the MRS and the Kupperman index were used to evaluate the severity of symptoms. The internal consistency coefficient (Cronbach's alpha) of the MRS was computed using the test-retest method. The influence of the MRS with regard to the decision to seek medical advice due to menopausal symptoms was considered the validity criterion, and the sensitivity and specificity of the test were established according to this criterion. Estimation values of the test were determined by ROC analysis. Independent variables for the severity of menopausal symptoms were determined using a logistic regression model.
RESULTS: A positive correlation between the MRS and the Kupperman index was revealed (r=0.86, p=0.000). The estimation value or the MRS score that would predict whether a woman had visited a gynecologist at least once due to the severity of menopause symptoms was found to be 16, its sensitivity and specificity were both 60%. The MRS score was higher among participants who evaluated their general health as 'unfit' or who had advanced age, chronic disease, a history of dysmenorrhea, or who had had two or more miscarriages.
CONCLUSIONS: This evaluation of the MRS indicates that the instrument is a comprehensible, useable, reliable screening test for the identification of women with severe menopausal symptoms. By screening using the MRS it is possible for primary healthcare workers in rural areas to identify women in need of referral to an upper-level healthcare institution.

Entities:  

Mesh:

Year:  2010        PMID: 20356316

Source DB:  PubMed          Journal:  Rural Remote Health        ISSN: 1445-6354            Impact factor:   1.759


  6 in total

1.  Health related lifestyle and preventive medical care of rural Spanish women compared to their urban counterparts.

Authors:  Ernesto De la Cruz-Sánchez; Loli Aguirre-Gómez
Journal:  J Immigr Minor Health       Date:  2014-08

2.  Frequency of symptoms, determinants of severe symptoms, validity of and cut-off score for Menopause Rating Scale (MRS) as a screening tool: a cross-sectional survey among midlife Nepalese women.

Authors:  Neena Chuni; Chandrashekhar T Sreeramareddy
Journal:  BMC Womens Health       Date:  2011-06-14       Impact factor: 2.809

3.  Risk of early menopausal symptoms in clinical workers.

Authors:  Seyedeh Negar Assadi
Journal:  Iran J Nurs Midwifery Res       Date:  2014-11

4.  Evaluation of the Effectiveness of Health Education on Menopause Symptoms and Knowledge and Attitude in Terms of Menopause.

Authors:  Tugce Koyuncu; Alaettin Unsal; Didem Arslantas
Journal:  J Epidemiol Glob Health       Date:  2018-12

5.  Correlation between the modified Kupperman Index and the Menopause Rating Scale in Chinese women.

Authors:  Minfang Tao; Hongfang Shao; Changbing Li; Yincheng Teng
Journal:  Patient Prefer Adherence       Date:  2013-03-20       Impact factor: 2.711

6.  Twelve-week exercise training and the quality of life in menopausal women - clinical trial.

Authors:  Jolanta Dąbrowska; Magdalena Dąbrowska-Galas; Magdalena Rutkowska; Bogdan Adam Michalski
Journal:  Prz Menopauzalny       Date:  2016-03-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.